Rapid development of affinity matured monoclonal antibodies using RIMMS

• Published in: Hybridoma Vol. 16; no. 4; p. 381
• Main Authors: Kilpatrick, K E, Wring, S A, Walker, D H, Macklin, M D, Payne, J A, Su, J L, Champion, B R, Caterson, B, McIntyre, G D
• Format: Journal Article
• Language: English
• Published: United States 01-08-1997
• Subjects: Animals; Antibodies, Monoclonal - immunology; Antibody Affinity; Antibody Specificity; B-Lymphocytes - immunology; Blotting, Western; Cloning, Molecular; Enzyme-Linked Immunosorbent Assay; Genes, bcl-2 - genetics; Haptens - immunology; Humans; Hybridomas - immunology; Immunization; Mice; Precipitin Tests; Tumor Cells, Cultured
• ISSN: 0272-457X
• DOI: 10.1089/hyb.1997.16.381

Affinity matured murine monoclonal antibody producing cell lines can now be rapidly generated using a novel repetitive, multiple site immunization strategy designated RIMMS. RIMMS capitalizes on rapid hypermutation and affinity maturation events which occur in B cell populations localized within secondary lymphatic tissue early in response to antigenic challenges. A murine myeloma cell line, P3XBcl-2-13, stably transfected with Bcl-2, enhances the outgrowth of hybridomas following somatic fusion with immune lymphocytes isolated from pooled peripheral lymph nodes (PLN) 8-14 days after the initial immunization. Immunizations somatic fusion, screening and isolation of affinity matured IgG secreting monoclonal antibody cell lines occur within a one month time period. By using RIMMS, we have been able to expedite the isolation of affinity matured monoclonal antibodies to numerous antigens, including a drug hapten.